Literature DB >> 7618932

Diminished concentrations of insulin-like growth factor I in cystic fibrosis.

E M Laursen1, A Juul, S Lanng, N Høiby, C Koch, J Müller, N E Skakkebaek.   

Abstract

Cystic fibrosis is frequently accompanied by a catabolic condition with low body mass index caused by a number of disease complications. Insulin-like growth factor-I (IGF-I) is an anabolic hormone and an important marker of nutritional status, liver function, and linear growth. Available data on IGF-I in cystic fibrosis are sparse and conflicting. From 1990-3, 235 of our 240 patients (114 males, 121 females, median age 16.2 years, ranged 0.1-44.0 years) had IGF-I measured once by radioimmunoassay. IGF-I was significantly reduced compared with a healthy Scandinavian control population: mean (-2 SD to +2 SD) IGF-I SD score was -0.97 (-3.7 to 1.7) in males and -0.67 (-3.2 to 1.9) in females. Height SD score was -0.95 (-3.3 to 1.4) in males and -0.81 (-3.2 to 1.6) in females. In patients who were still in the growth period a significant correlation of IGF-I SD score to height SD score (r = 0.28, p < 0.001) was found. The low IGF-I concentrations may reflect the catabolic state of many patients with cystic fibrosis and play a part in their abnormal growth pattern.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618932      PMCID: PMC1511133          DOI: 10.1136/adc.72.6.494

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  16 in total

1.  Glucose tolerance in cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; G Erichsen; J Nerup; C Koch
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

Review 2.  Clinical review 35: Growth factors and their potential clinical value.

Authors:  E Canalis
Journal:  J Clin Endocrinol Metab       Date:  1992-07       Impact factor: 5.958

3.  Liver disease and bile duct abnormalities in adults with cystic fibrosis.

Authors:  R A Nagel; D Westaby; A Javaid; J Kavani; H B Meire; M G Lombard; A Wise; R Williams; M E Hodson
Journal:  Lancet       Date:  1989-12-16       Impact factor: 79.321

4.  Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation.

Authors:  H K Johansen; M Nir; N Høiby; C Koch; M Schwartz
Journal:  Lancet       Date:  1991-03-16       Impact factor: 79.321

5.  Demonstration of normal plasma somatomedin concentrations in cystic fibrosis.

Authors:  R G Rosenfeld; C Landon; N Lewiston; R Nagashima; R L Hintz
Journal:  J Pediatr       Date:  1981-08       Impact factor: 4.406

6.  Abnormal growth hormone dynamics in chronic liver disease do not depend on severe parenchymal disease.

Authors:  S N Assaad; G R Cunningham; N A Samaan
Journal:  Metabolism       Date:  1990-04       Impact factor: 8.694

7.  Plasma insulin-like growth factor-I determinations in patients with cystic fibrosis: Influence of the nutritional and liver status.

Authors:  J De Schepper; M Van Blerk; S Hachimi-Idrissi; I Dab; J Smitz
Journal:  Clin Nutr       Date:  1992-10       Impact factor: 7.324

8.  Endocrine and exocrine pancreatic function and the delta F508 mutation in cystic fibrosis.

Authors:  S Lanng; M Schwartz; B Thorsteinsson; C Koch
Journal:  Clin Genet       Date:  1991-11       Impact factor: 4.438

9.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index.

Authors:  A Juul; P Bang; N T Hertel; K Main; P Dalgaard; K Jørgensen; J Müller; K Hall; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

10.  Insulin-like growth factors (IGF) in liver disease: differential changes of IGF-I and IGF-II.

Authors:  M S Sheppard; G Y Minuk; B Bhaumick; R M Bala
Journal:  Clin Invest Med       Date:  1987-03       Impact factor: 0.825

View more
  12 in total

1.  Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.

Authors:  F De Benedetti; T Alonzi; A Moretta; D Lazzaro; P Costa; V Poli; A Martini; G Ciliberto; E Fattori
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Insulin-like growth factor I response during nutritional rehabilitation of persistent diarrhoea.

Authors:  Z A Bhutta; P Bang; E Karlsson; L Hagenäs; S Q Nizami; O Söder
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

3.  Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis.

Authors:  A M Taylor; A Bush; A Thomson; P J Oades; J L Marchant; C Bruce-Morgan; J Holly; L Ahmed; D B Dunger
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

4.  Clinical and genetic analyses of presumed Shwachman-Diamond syndrome in Japan.

Authors:  Hiromichi Taneichi; Hirokazu Kanegane; Takeshi Futatani; Keisuke Otsubo; Keiko Nomura; Yuya Sato; Asahito Hama; Seiji Kojima; Urara Kohdera; Takahide Nakano; Hiroki Hori; Hisashi Kawashima; Yoko Inoh; Junji Kamizono; Naoto Adachi; Yuko Osugi; Haruo Mizuno; Noriko Hotta; Hiroshi Yoneyama; Eiji Nakashima; Shiro Ikegawa; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

5.  Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life.

Authors:  Daniel H Leung; Sonya L Heltshe; Drucy Borowitz; Daniel Gelfond; Margaret Kloster; James E Heubi; Michael Stalvey; Bonnie W Ramsey
Journal:  JAMA Pediatr       Date:  2017-06-01       Impact factor: 16.193

6.  Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations.

Authors:  A H Gifford; A B Nymon; A Ashare
Journal:  Pediatr Pulmonol       Date:  2013-06-18

7.  Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis.

Authors:  C M Gordon; E Binello; M S LeBoff; M E Wohl; C J Rosen; A A Colin
Journal:  Osteoporos Int       Date:  2006-03-16       Impact factor: 4.507

Review 8.  Growth hormone and exercise tolerance in patients with cystic fibrosis.

Authors:  Matthias Hütler; Ralph Beneke
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients.

Authors:  I Sermet-Gaudelus; J C Souberbielle; I Azhar; J C Ruiz; P Magnine; V Colomb; C Le Bihan; D Folio; G Lenoir
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

10.  Growth failure and treatment in cystic fibrosis.

Authors:  Trang N Le; Abeer Anabtawi; Melissa S Putman; Vin Tangpricha; Michael S Stalvey
Journal:  J Cyst Fibros       Date:  2019-10       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.